comprehensive -WSS

comprehensive

author：hotspot 2025-09-06 03:26:33 - browse：44671

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Reanimated hearts work just as well for transplants, study finds

Wikipedia

knowledge

WSS

Can medical device makers keep up in the race to treat obesity?

Cue Health, Covid

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

A public health expert passes on football's full body collisions for youths

Study finds gene variants tied to breast cancer risk in Black women

leisure time

comprehensive

focus

Alkermes shareholders re

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Moonlake's readout produced a cash windfall. Risks remain

Liver decline slowed by off

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Reports of telehealth's death have been greatly exaggerated

Hollywood unions extend contract negotiations for actors

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

leisure time

Digital health: a case of mistaken identity

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Digital health: a case of mistaken identity

UnitedHealth argues against case alleging wrongful AI care denials

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Questions and answers about ramping up H5N1 bird flu vaccine

Wikipedia

hotspot

knowledge

focus